# Adjuvant Autologous Platelet‐Rich Plasma Gel for Decreasing Blood Loss in Posterior Placenta Previa: A Case Series and Literature Review

**Authors:** Chatuporn Duangkum, Wiyada Punjaruk, Thitinan Kasetthat, Hathairat Buraphaka, Jatupong Sitsutheechananon, Thanida Thanoorat

PMC · DOI: 10.1155/crog/9480876 · Case Reports in Obstetrics and Gynecology · 2026-02-18

## TL;DR

This case series explores using platelet-rich plasma gel during cesarean deliveries for posterior placenta previa to reduce blood loss.

## Contribution

The study introduces the use of autologous PRP gel as an adjuvant to manage blood loss in posterior placenta previa.

## Key findings

- PRP gel application resulted in minimal postoperative blood loss in two cases of posterior placenta previa.
- No blood transfusions were required in either case following PRP gel use.
- Hematocrit levels remained relatively stable in both patients after the procedure.

## Abstract

We reported two cases of posterior placenta previa managed with elective cesarean delivery and adjunctive autologous platelet‐rich plasma (PRP) gel. Twelve milliliters of PRP gel were used to cover both the sutured implantation site and the denuded area in both cases. Case 1, gravida 1, para 0 with 37 1/7 weeks′ gestation, intra‐ and 24‐h postoperative blood loss were 400 and 10 mL, respectively, whereas the hematocrit decreased from 34.4% to 29.4%. Case 2, gravida 2, para 1, with a gestation of 37 4/7 weeks, had intra‐ and 24‐h postoperative blood loss of 500 and 50 mL, respectively. The hematocrit changed from 32.8% to 32%. No blood transfusion was required in either case.

Adjuvant autologous PRP gel may reduce blood loss in posterior placenta previa. Further optimization of PRP preparation protocols for pregnant women, along with validation through large‐scale clinical trials, is warranted to confirm their effectiveness and generalizability.

## Linked entities

- **Diseases:** placenta previa (MONDO:0005918)

## Full-text entities

- **Genes:** TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, VTN (vitronectin) [NCBI Gene 7448] {aka V75, VN, VNT}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}
- **Diseases:** fistula (MESH:D005402), urological tract injury (MESH:D014570), sepsis (MESH:D018805), thromboembolic (MESH:D013923), postoperative (MESH:D019106), postpartum hemorrhage (MESH:D006473), preterm birth (MESH:D047928), infection (MESH:D007239), respiratory distress syndrome (MESH:D012128), multiple organ failure (MESH:D009102), PAS (MESH:D010921), bleeding (MESH:D006470), acute kidney ischemia (MESH:D058186), Blood Loss (MESH:D016063), bowel injury (MESH:D012778), Placenta previa (MESH:D010923)
- **Chemicals:** citrate dextrose (-), Carbetocin (MESH:C020731), calcium gluconate (MESH:D002125)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12914217/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12914217/full.md

## References

21 references — full list in the complete paper: https://tomesphere.com/paper/PMC12914217/full.md

---
Source: https://tomesphere.com/paper/PMC12914217